A number of firms have modified their ratings and price targets on shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) recently:

  • 10/23/2017 – Eiger BioPharmaceuticals was given a new $34.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 10/19/2017 – Eiger BioPharmaceuticals is now covered by analysts at Roth Capital. They set a “buy” rating and a $35.00 price target on the stock.
  • 10/17/2017 – Eiger BioPharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. “
  • 10/16/2017 – Eiger BioPharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. “
  • 9/25/2017 – Eiger BioPharmaceuticals had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $34.00 price target on the stock.
  • 9/1/2017 – Eiger BioPharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.

Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) opened at 12.00 on Tuesday. The firm’s market cap is $100.40 million. Eiger BioPharmaceuticals, Inc. has a 1-year low of $6.10 and a 1-year high of $13.95. The company’s 50-day moving average is $11.45 and its 200 day moving average is $8.75.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.05). On average, equities research analysts expect that Eiger BioPharmaceuticals, Inc. will post ($5.21) EPS for the current fiscal year.

In other news, Director Jeffrey S. Glenn purchased 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average cost of $9.53 per share, with a total value of $142,950.00. Following the acquisition, the director now directly owns 31,355 shares of the company’s stock, valued at approximately $298,813.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 28.80% of the company’s stock.

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Receive News & Ratings for Eiger BioPharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.